BindingDB logo
myBDB logout

40 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
25654260 49 Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.EBI F. Hoffmann-La Roche Ltd.
25642985 45 Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.EBI UMR7200 CNRS/Universit£ de Strasbourg
24874785 333 New, potent, and selective peptidic oxytocin receptor agonists.EBI Ferring Research Institute Inc.
16250654 41 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.EBI GlaxoSmithKline Research and Development
21700453 56 Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.EBI MSD
21458261 55 The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.EBI MSD
21146408 53 The characterization of a novel V1b antagonist lead series.EBI GlaxoSmithKline Research and Development
20674355 58 Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.EBI GlaxoSmithKline
19081251 38 Discovery and optimisation of a potent and selective tertiary sulfonamide oxytocin antagonist.EBI GlaxoSmithKline Pharmaceuticals
22984902 59 Selective fluorescent nonpeptidic antagonists for vasopressin V2 GPCR: application to ligand screening and oligomerization assays.EBI UMR7200 CNRS/Universit£ de Strasbourg
22239250 59 Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.EBI GlaxoSmithKline Research and Development
22425346 28 Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors.EBI Emory University
19800231 92 Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.EBI Schering-Plough Research Institute
18032036 17 The discovery of GSK221149A: a potent and selective oxytocin antagonist.EBI GlaxoSmithKline Research and Development
17850055 18 Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.EBI INSERM
16302826 129 Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.EBI Serono Pharmaceutical Research Institute
15084136 96 Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.EBI Medical College of Ohio
12036367 46 Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.EBI INSERM
22249122 9 Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.EBI Lehigh University
21688787 295 New, potent, selective, and short-acting peptidic V1a receptor agonists.EBI Ferring Research Institute Inc.
21605973 69 Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties.EBI Abbott
21601454 26 Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.EBI MSD
21596563 33 Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.EBI MSD
21428295 43 Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.EBI INSERM
21353540 55 Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.EBI MSD
20550119 96 Oral oxytocin antagonists.EBI DrugMolDesign
20719508 26 Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists.EBI Ligand Pharmaceuticals, Inc.
18778939 23 Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent.EBI Pfizer Global Research and Development
10197974 22 Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications.EBI INSERM
12660315 17 Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.BDB LCG Bioscience
12649361 779 L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.BDB Case Western Reserve University
12192085 52 Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.BDB Case Western Reserve University
12110997 380 In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs.BDB Westfälische Wilhelms-Universitä Muenster,
11861823 10 Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.BDB Sanofi-Synthelabo Recherche
11512051 80 The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor.BDB Case Western Reserve University
9864265 14 OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.BDB Second Tokushima Institute of New Drug Research
9454810 72 SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.BDB Sanofi Recherche